Details of the Drug

General Information of Drug (ID: DM6OKBJ)

Drug Name
Ropidoxuridine
Synonyms IPdR; IPdR (LADD), Hana; IPdR, (LADD) SuperGen; 5-iodo-pyrimidinone-2'-deoxyribose; 5-iodo-pyrimidinone-2-deoxyribose (LADD), SuperGen
Indication
Disease Entry ICD 11 Status REF
Gastrointestinal cancer 2C11 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C9H11IN2O4
Canonical SMILES
C1C(C(OC1N2C=C(C=NC2=O)I)CO)O
InChI
1S/C9H11IN2O4/c10-5-2-11-9(15)12(3-5)8-1-6(14)7(4-13)16-8/h2-3,6-8,13-14H,1,4H2/t6-,7+,8+/m0/s1
InChIKey
XIJXHOVKJAXCGJ-XLPZGREQSA-N
Cross-matching ID
PubChem CID
9840777
CAS Number
93265-81-7
UNII
3HX21A3SQF
DrugBank ID
DB06485
TTD ID
D09WGH
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02381561) Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy. U.S. National Institutes of Health.